Based on the draft yearly....
Company is confident of achieving 250 million annual sales milestone in the future.
250 million represents about 200,000 sales ( where average US patient gets 2 months supply. )
This is slightly less than my estimate for Kakens sales last FY. Meaning if BOT only match Kaken they will hit 250 million in annual sales. Remember, Kaken was over 100,000 annual sales straight out of the gate on day dot.
That is a tiny market penetration... 2% of all sufferers, or 5.4% of sufferers paying for treatment
Given the doctors survey indicated closer to 50% intended use..
I think 20-30% at least ( 1 billion us sales ), is on the cards here
2025 sales ramp will be very telling.
Sofdra US Sales Curve, page-31
-
- There are more pages in this discussion • 82 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $671.1M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 38.0¢ | 36.5¢ | $827.7K | 2.229M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 99032 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 13677 | 1 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |